Back to mobile site

Oppenheimer Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)

March 12, 2025 8:35 AM EDT Send to a Friend
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $78.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst comments "IONS ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login